Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006187 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 3
- Development phase
NCT00006187: Clinical Trial Phase 3 study, sponsored by Merck Sharp & Dohme.
NCT00006187 is a Phase 3 study that was terminated before completion, run by Merck Sharp & Dohme. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006187, a Phase 3 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 3
- Development phase
Study Summary
This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month randomized withdrawal period. For this phase approximately 10% of the patients will remain on the active drug.
Interventions
- DRUG Investigational drug
Trial Details
| Field | Value |
|---|---|
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Why NCT00006187 stopped before completion
NCT00006187 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Investigational drug is the first listed.
NCT00006187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006187 about?
NCT00006187 is a clinical study titled "The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease". This is a 15-month study with two phases. During the first 12-month phase of this study, patients will be randomly assigned to receive either active study drug or placebo (approximately half of all patients will be on active study drug, the other half on placebo). The second phase is a 3-month rando...
What is the current status of trial NCT00006187?
This trial is currently terminated. It is a Phase 3 study. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00006187?
The interventions under investigation include: Investigational drug (DRUG).
Who is sponsoring clinical trial NCT00006187?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.